Chunghwa Chemical Synthesis & Biotech Co., Ltd.

TWSE:1762 Stock Report

Market Cap: NT$2.6b

Chunghwa Chemical Synthesis & Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chunghwa Chemical Synthesis & Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth8.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 22
Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems

Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet

Nov 14
Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Aug 09
Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Jul 12
Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80

Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04
Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems

A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Apr 01
A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)

Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Mar 04
Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

Jan 28
What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend

Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

Jan 02
Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?

The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

Dec 06
The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chunghwa Chemical Synthesis & Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TWSE:1762 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20241,51798179307N/A
6/30/20241,507118-161-2N/A
3/31/20241,573126-472-306N/A
12/31/20232,086265-518-66N/A
9/30/20232,173290-46869N/A
6/30/20232,300399-96435N/A
3/31/20232,353517-16578N/A
12/31/20222,117466358734N/A
9/30/20222,082488309685N/A
6/30/20222,122452136541N/A
3/31/20222,043430-222257N/A
12/31/20211,935401-186219N/A
9/30/20211,987408-22286N/A
6/30/20211,766358-198107N/A
3/31/20211,65860230230N/A
12/31/20201,544532-55138N/A
9/30/20201,26047028212N/A
6/30/20201,193461118267N/A
3/31/20201,120104150261N/A
12/31/20191,157117153268N/A
9/30/20191,11376108231N/A
6/30/20191,07427087199N/A
3/31/20191,08727227140N/A
12/31/20181,019234141235N/A
9/30/20181,131286-267318N/A
6/30/20181,313129N/A349N/A
3/31/20181,172101N/A260N/A
12/31/20171,16886N/A159N/A
9/30/20171,12667N/A160N/A
6/30/20171,10019N/A141N/A
3/31/20171,20431N/A224N/A
12/31/20161,19960N/A261N/A
9/30/20161,25494N/A218N/A
6/30/20161,185112N/A223N/A
3/31/20161,181125N/A254N/A
12/31/20151,162308N/A80N/A
9/30/20151,098246N/A92N/A
6/30/2015995193N/A-48N/A
3/31/2015945203N/A-55N/A
12/31/201494715N/A23N/A
9/30/201492317N/A-4N/A
6/30/201496546N/A103N/A
3/31/201499567N/A124N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 1762's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 1762's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 1762's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1762's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 1762's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 1762's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 07:04
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chunghwa Chemical Synthesis & Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yenya KuoCapital Securities Corporation
Ryan LiuIBTS Investment Consulting Co., Ltd.
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.